Business Model ― Value Creation Process
Sumitomo Pharma Group is working towards realizing a sustainable
society guided by our corporate Philosophy: "To broadly contribute
to society through value creation based on innovative research and
development activities for the betterment of healthcare and fuller
lives of people".
To put our Philosophy into practice, we are
addressing ten Material Issues such as “Development of
innovative products and healthcare solutions” through business
activities that leverage our three strengths (R&D, human
resources, and global platform) based on our six types of capital,
as well as providing solutions that meet diverse medical needs.
We
will continue to work to embody our Philosophy, aiming to establish
Sumitomo Pharma as a “Global Specialized Player (GSP)”.
For more information on Material Issues, please see "Material Issues."
Stakeholder Engagement
We, as a good corporate citizen, need to have a very wide perspective in order to address the multiple issues our modern society faces. We strive to enhance both social sustainability and our corporate value through dialogue and collaboration with all of our stakeholders including patients and their families, healthcare professionals, employees, shareholders and investors, collaboration partners, business partners and local communities.
Engagement with Stakeholders
| Stakeholder | Main Activities |
|---|---|
| Patients and Families |
・Responding to inquiries about products ・Providing health-related information ・Encouraging patient involvement |
| Healthcare Professionals |
・Providing and collecting medical information through medical
representatives (MRs)
・Operating dedicated websites for healthcare professionals |
| Employees |
・Promoting employee health, safety and welfare ・Training and developing employees ・Promoting Diversity and Inclusion ・Conducting employee surveys |
| Shareholders and Investors |
・Holding Shareholders’ Meeting and Conference on Financial
Results ・Publishing integrated reports ・Disclosing ESG information |
Government and Industry Associations | ・Participating in economic and industry organizations and various external initiatives |
| Research Institutions | ・Conducting joint research | Business Partners |
・Ensuring fair transactions ・Promoting sustainable procurement |
| NGOs and NPOs |
・Advancing initiatives to improve access to medicines ・Contributing to global health |